From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer's Disease?

Maria Laura Bolognesi (Lead / Corresponding author), Annachiara Gandini, Federica Prati, Elisa Uliassi

Research output: Contribution to journalReview articlepeer-review

38 Citations (Scopus)
403 Downloads (Pure)


The recent literature signals a growing paradigm shift toward integrating therapeutics and diagnostics rather than developing and deploying them separately. In this gradual move toward more effective and personalized medications, companion diagnostics are an intermediate stage. The next step may be "theranostics", in which single chemical entities are developed to deliver therapy and diagnosis simultaneously. This strategy has been successfully exploited in oncology and is now emerging as a possibility for Alzheimer's disease, where its feasibility has caught the attention of researchers from industry and academia. Medicinal chemists do not yet completely understand the nuances of theranostic action and consequently have not yet developed universally validated strategies for developing theranostic clinical applications against Alzheimer's disease. However, given the emerging indications of the potentially enormous benefits that theranostics may bring to the fight against this devastating disease, further rigorous research is warranted.

Original languageEnglish
Pages (from-to)7759-7770
Number of pages12
JournalJournal of Medicinal Chemistry
Issue number17
Early online date28 Apr 2016
Publication statusPublished - 8 Sept 2016

ASJC Scopus subject areas

  • General Medicine
  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer's Disease?'. Together they form a unique fingerprint.

Cite this